MedTrace Logo

Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD

NCT00370370 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2008-06-26

No results posted yet for this study

Summary

To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab + triamcinolone acetonide in neovascular AMD.

Conditions

  • Neovascular Age-Related Macular Degeneration

Interventions

DRUG

bevacizumab

Injection of intravitreal bevacizumab

DRUG

bevacizumab + triamcinolone acetonide

Injection of bevacizumab + triamcinolone acetonide

Sponsors & Collaborators

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Principal Investigators

  • Hamid Ahmadieh, MD · Ophthalmic Research Center of Shaheed Beheshti Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00370370 on ClinicalTrials.gov